GGrantIndex
Sort

39,280 grants matching leukemia

Clinical Trials Evaluating Transplant Strategies and Adoptive Cell Therapies to

$400,570
Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2017 · CA

MOLECULAR MECHANISMS OF NUCLEIC ACID DAMAGE BY ENEDIYNES

$400,552
Harvard University (Medical School) · R01 · FY2003 · GM

MOLECULAR BIOLOGY OF HUMAN MYELOID DIFFERENTIATION

$400,491
Beth Israel Deaconess Medical Center · R01 · FY2002 · CA

SOLID STATE RADIATION CHEMISTRY OF DNA

$400,489
University Of Rochester · R01 · FY2002 · CA

Explore the signaling mechanisms of acquired resistance to tyrosine kinase inhibitors in AML

$400,445
Jian Huang · Coriell Institute For Medical Research · R01 · FY2023 · CA

Explore the signaling mechanisms of acquired resistance to tyrosine kinase inhibitors in AML

$400,445
Jian Huang · Coriell Institute For Medical Research · R01 · FY2022 · CA

Occupational Exposure Assessment

$400,216
Melissa Friesen · Division Of Cancer Epidemiology And Genetics · ZIA · FY2021 · CA

Co-targeting S6 and TAM kinases in PTEN-deficient glioblastoma

$400,209
David R Plas · University Of Cincinnati · R01 · FY2024 · CA

Physiologic Regulation of Hematopoiesis by Notch

$400,188
Nadia Carlesso · Indiana University Indianapolis · R01 · FY2015 · DK

Nuclear Receptor Functional Profiling in Metabolism and Disease

$400,172
Ronald M. Evans · Baylor College Of Medicine · U19 · FY2009 · DK

Nuclear Receptor Functional Profiling in Metabolism and Disease

$400,172
Ronald M. Evans · Baylor College Of Medicine · U19 · FY2008 · DK

Nuclear Receptor Functional Profiling in Metabolism and Disease

$400,171
Ronald M. Evans · Baylor College Of Medicine · U19 · FY2010 · DK

Understanding the role of histone 3 lysine 4 trimethylation in neonatal innate immune development under normal and inflammatory conditions

$400,162
Jennifer Bermick · University Of Michigan At Ann Arbor · R01 · FY2020 · AI

Community Clinical Oncology Program

$400,119
Northshore Univ Healthsystem Res Inst · U10 · FY2004 · CA

Tissue-specific tumor suppressor effects of p53

$400,089
James J. Manfredi · Icahn School Of Medicine At Mount Sinai · R01 · FY2015 · CA

Validating a novel biomarker of clinical progression and survival in CLL

$400,042
Randall S Davis · University Of Alabama At Birmingham · R33 · FY2012 · CA

Function and Biology of Eukaryotic DNA Topoisomerases

$400,040
Neil Osheroff · Vanderbilt University · R01 · FY2015 · GM

Targeting AML Mitochondria by Ceramide

$400,000
Besim Ogretmen · Lipo-Immuno Tech, Llc · R41 · FY2022 · CA

Immune privilege of the hematopoieitic stem cell niche

$400,000
Joji Fujisaki · Columbia University Health Sciences · R01 · FY2016 · HL

Gene and Cytokine Expression in Tolerance and GVHD

$400,000
Samuel Strober · Stanford University · R01 · FY2009 · AI

Yes1 as a quiescence regulator in hematopoietic stem cells

$400,000
Siddhartha Mukherjee · Columbia University Health Sciences · R01 · FY2017 · HL

Immune privilege of the hematopoieitic stem cell niche

$400,000
Joji Fujisaki · Columbia University Health Sciences · R01 · FY2017 · HL

Engineering in vivo half-life extension of a novel mammalian asparaginase to increase feasibility of pan-cancer therapy

$400,000
Amanda M Schalk · Enzyme By Design, Inc. · R43 · FY2024 · CA

A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients

$400,000
Aaron D Schuler · Syntrix Biosystems, Inc. · R44 · FY2024 · CA

CAREER: Advancing Model Predictive Control of Cell Differentiation

$400,000
Ann Rundell · Purdue University · · FY2009 · ENG